Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Tissue Repair.
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX axed in regional rout while mini-biotech Tissue Repair soars on TGA nod
Health & Biotech
ASX Health Stocks: dorsaVi up 27pc on US deals, Starpharma reports positive outcome on Phase 2 trial
News
Market Highlights: Amazon up, gold price prediction, and 5 ASX small caps to watch today
Health & Biotech
REPORT: ASX wound care is rapidly becoming an ‘exciting subsector’
Health & Biotech
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Health & Biotech
ASX Health Stocks: Tissue Repair and Radiopharm jump double digits after US FDA meetings
IPO Watch
Most ASX growth stocks have taken a beating in 2022. Are there oversold IPOs among them?
Health & Biotech
ASX Health Stocks: Tissue Repairs granted second patent in US; Clarity to start Phase 2 recruitment
Health & Biotech
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
Health & Biotech
ASX Health Stocks: Tissue Repairs delivers on prospectus promise as it pockets first patent in the US
IPO Watch
IPO Watch: ASX IPOs in 2021 were up 14 per cent on average; here are the best performers
IPO Watch
IPO Watch: These companies are making a late charge up the winners’ list
News
Trading Places: Which recent ASX IPO saw investees top up their holdings on market?
Health & Biotech
ASX Health: 4D Medical jumps 16pc on lungs device rollout, Proteomics up 10pc on UK deal
News
ASX Capital Raise Roundup: Fighting inflation the Dalio way – with some retail therapy
Health & Biotech
ScoPo’s Powerplays: Investors look to Healthcare for ESG exposure, and Volpara is the poster child
News
